reports
- Wedbush Research
XNCR XENCOR INC.
TRNO TERRENO REALTY CORPORATION
TRIP TRIPADVISOR INC.
STAG STAG INDUSTRIAL INC.
REXR REXFORD INDUSTRIAL REALTY INC.
PEGA PEGASYSTEMS INC.
NVCR NOVOCURE LTD.
MTH MERITAGE HOMES CORPORATION
KURA KURA ONCOLOGY INC.
IMAX IMAX CORPORATION
FR FIRST INDUSTRIAL REALTY TRUST INC.
FATE FATE THERAPEUTICS INC
EXPE EXPEDIA GROUP INC.
EGP EASTGROUP PROPERTIES INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
CCS CENTURY COMMUNITIES INC.
ANAB ANAPTYSBIO INC.
PLYM PLYMOUTH INDUSTRIAL REIT INC.
MRSN MERSANA THERAPEUTICS
ISR ISORAY
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
BKNG BOOKING HOLDINGS INC.
RCUS ARCUS BIOSCIENCES
HEAR TURTLE BEACH CORP.
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
CRSR CORSAIR GAMING
ITOS ITEOS THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
COGT COGENT BIOSCIENCES INC
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
RBLX ROBLOX
DAWN DAY ONE BIOPHARMACEUTICALS INC
FHTX FOGHORN THERAPEUTICS
TNGX TANGO THERAPEUTICS
GLUE INC
CMPX MONTE ROSA THERAPEUTICS INC
JANX COMPASS THERAPEUTICS
YOU JANUX THERAPEUTICS INC
TYRA CLEAR SECURE INC
ARTV TYRA BIOSCIENCES INC
CRBP ARTIVA BIOTHERAPEUTICS INC
BCAX CORBUS PHARMACEUTICALS HOLDINGS INC.
BICARA THERAPEUTICS INC.
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
NVCR NOVOCURE LTD.
KURA KURA ONCOLOGY INC.
FATE FATE THERAPEUTICS INC
ANAB ANAPTYSBIO INC.
MRSN MERSANA THERAPEUTICS
ISR ISORAY
RCUS ARCUS BIOSCIENCES
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
ITOS ITEOS THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
COGT COGENT BIOSCIENCES INC
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
FHTX FOGHORN THERAPEUTICS
TNGX TANGO THERAPEUTICS
GLUE INC
CMPX MONTE ROSA THERAPEUTICS INC
JANX COMPASS THERAPEUTICS
TYRA JANUX THERAPEUTICS INC
NUVL TYRA BIOSCIENCES INC
ARTV NUVALENT INC
CRBP ARTIVA BIOTHERAPEUTICS INC
BCAX CORBUS PHARMACEUTICALS HOLDINGS INC.
BICARA THERAPEUTICS INC.
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 D...
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting SEATTLE, April 23, 2025 (GLOBE NEWSWIRE) -- (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that data on the Company’s [212Pb]VMT-α-NET and [212Pb]VMT01 programs have been accepted for presentation as detailed below at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3, 2025 in Chicago, Illinois. ASCO plans...
Perspective Therapeutics to Provide Business Highlights and Report Fir...
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results SEATTLE, April 17, 2025 (GLOBE NEWSWIRE) -- (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May 12, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at . About Perspective Therapeutics, Inc. Perspectiv...
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT...
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma SEATTLE, April 11, 2025 (GLOBE NEWSWIRE) -- ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), as monotherapy in patients with histologically confirmed melanoma and positiv...
- Jonathan Moreland
ULTA ULTA BEAUTY INC
STAA STAAR SURGICAL CO.
SIGI SELECTIVE INSURANCE GROUP INC.
SIG SIGNET JEWELERS LIMITED
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
PSEC PROSPECT CAPITAL CORPORATION
PEB PEBBLEBROOK HOTEL TRUST
OSUR ORASURE TECHNOLOGIES INC.
OPK OPKO HEALTH INC.
OMCL OMNICELL INC.
MTDR MATADOR RESOURCES COMPANY
MEI METHODE ELECTRONICS INC.
JCOM J2 GLOBAL INC.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HUN HUNTSMAN CORPORATION
HSII HEIDRICK & STRUGGLES INTERNATIONAL INC.
HSC
I3N HARSCO CORPORATION
FSS CHART INDUSTRIES INC.
EVH FEDERAL SIGNAL CORPORATION
ECPG EVOLENT HEALTH INC CLASS A
CMC ENCORE CAPITAL GROUP INC.
APPS COMMERCIAL METALS COMPANY
AMRC DIGITAL TURBINE
ADBE AMERESCO
HRTG ADOBE INC.
FMC HERITAGE INSURANCE HOLDINGS INC.
MAC FMC CORPORATION
LIVE MACERICH COMPANY
FLGT LIVE VENTURES
FCNCA FULGENT GENETICS
DMLP FIRST CITIZENS BANCSHARES INC. CLASS A
RCII DORCHESTER MINERALS L.P.
FTDR RENT-A-CENTER INC
NFE FRONTDOOR INC.
GRWG NEW FORTRESS ENERGY
PCB GROWGENERATION
CMPR PACIFIC CITY FINANCIAL CORP
RC CIMPRESS PLC
ACA GRUPO RADIO CENTRO S.A.B. DE C.V.
RZLT ARCOSA
ONEW REZOLUTE
PRLD INC.
FET ONEWATER MARINE
IMNM PRELUDE THERAPEUTICS
CMTG FORUM ENERGY TECHNOLOGIES
LYEL IMMUNOME
BTMD CLAROS MORTGAGE TRUST
IE INC.
EBC LYELL IMMUNOPHARMA INC
MODD HAYMAKER ACQUISITION CORP III
MRNA IVANHOE ELECTRIC INC
FG EASTERN BANKSHARES INC
MODULAR MEDICAL INC
MODERNA
INC.
F AND G ANNUITIES AND LIFE
INC.
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of International Flavors & Fragrances, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 26 March 2025 in which we reassessed the appropriateness of the ra...
- Wedbush Research
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PRGS PROGRESS SOFTWARE CORPORATION
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
MNRO MONRO INC
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
SAFE SAFEHOLD INC.
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
ATXS ASTRIA THERAPEUTICS INC
AVTE AEROVATE THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
ATXS ASTRIA THERAPEUTICS INC
AVTE AEROVATE THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
Perspective Therapeutics to Participate in Upcoming April Investor Con...
Perspective Therapeutics to Participate in Upcoming April Investor Conferences SEATTLE, March 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. 24th Annual Needham Virtual Healthcare Conference - 1x1s OnlyDate: Monday, April 7, 202...
- Wedbush Research
Perspective Therapeutics Provides Recent Business Highlights and Repor...
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our next generation targeted radiopharmaceutical technology platformEnrollment ongoing for VMT-α-NET, a next generation SSTR2-targeting potential new medicine, with 30 patients enrolled through end of February 2025 in Cohort 2 of the Phase 1/2a trial in neuroendocrine tumorsAchieved first-in-human combin...
- David Nierengarten
- Dennis Pak
- Martin Fan
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. “We are thrilled to welcome Michael to Avalo’s Board of Directors during...
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
Avalo Reports 2024 Financial Results and Recent Business Updates
Avalo Reports 2024 Financial Results and Recent Business Updates Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial ...
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT...
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), in patients with histologically confirmed melanoma...
- David Nierengarten
- Dennis Pak
- Martin Fan
- Jonathan Moreland
WWW WOLVERINE WORLD WIDE INC.
TTSH TILE SHOP HOLDINGS INC.
TRS TRIMAS CORPORATION
STAA STAAR SURGICAL CO.
SRE SEMPRA ENERGY
SIGI SELECTIVE INSURANCE GROUP INC.
SEDG SOLAREDGE TECHNOLOGIES INC.
PEB PEBBLEBROOK HOTEL TRUST
PBF PBF ENERGY INC. CLASS A
OSUR ORASURE TECHNOLOGIES INC.
MTDR MATADOR RESOURCES COMPANY
LTRX LANTRONIX INC.
JCOM J2 GLOBAL INC.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FRPT FRESHPET INC
ECPG ENCORE CAPITAL GROUP INC.
CDXS CODEXIS
AMRC AMERESCO
CMCO COLUMBUS MCKINNON CORPORATION
FMC FMC CORPORATION
PETS PETMED EXPRESS INC.
PLBC PLUMAS BANCORP
FLWS 1-800-FLOWERS.COM CL A
JELD JELD-WEN HOLDING INC.
FRAF FRANKLIN FINANCIAL SERVICES CO.
FTDR FRONTDOOR INC.
STRA STRATEGIC EDUCATION INC.
LBSRD LIBERTY STAR URANIUM & METALS
AMCR AMCOR PLC
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
PSN PARSONS
PCB PACIFIC CITY FINANCIAL CORP
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
ORIC ORIC PHARMACEUTICALS
NOG NORTHERN OIL AND GAS
UAN CVR PARTNERS LP
CLVT CLARIVATE PLC
FLNC FLUENCE ENERGY INC
BHVN BIOHAVEN LTD
ECAT BLACKROCK ESG CAP ALLOCATION TR
MAIA MAIA BIOTECHNOLOGY INC
MBC_w MASTERBRAND INC
MRNA MODERNA
CVI INC.
BHRB CVR ENERGY
GF INC.
BURKE HERBERT FINANCIAL SERVICES CORP
THE NEW GERMANY FUND
INC.
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
TRS TRIMAS CORPORATION
TDOC TELADOC HEALTH INC.
STAA STAAR SURGICAL CO.
SEDG SOLAREDGE TECHNOLOGIES INC.
MTDR MATADOR RESOURCES COMPANY
LTRX LANTRONIX INC.
JCOM J2 GLOBAL INC.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
I3N CHART INDUSTRIES INC.
ECPG ENCORE CAPITAL GROUP INC.
CDXS CODEXIS
BUSE FIRST BUSEY CORPORATION
AMRC AMERESCO
FMC FMC CORPORATION
JELD JELD-WEN HOLDING INC.
STRA STRATEGIC EDUCATION INC.
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
PCB PACIFIC CITY FINANCIAL CORP
RC GRUPO RADIO CENTRO S.A.B. DE C.V.
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
ONEW ONEWATER MARINE
FLNC FLUENCE ENERGY INC
LSF LAIRD SUPERFOOD INC
ECAT BLACKROCK ESG CAP ALLOCATION TR
BHRB BURKE & HERBERT BANK & TR/VA
SBGI SINCLAIR INC
CUBA THE HERZFELD CARIBBEAN BASIN FUND
PSBD INC.
GAM PALMER SQUARE CAPITAL BDC INC
GF GENERAL DE ALQUILER DE MAQUINARIA
THE NEW GERMANY FUND
INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.